deltatrials
Completed PHASE2 NCT00137852

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer

Sponsor: Brigham and Women's Hospital

Conditions Esophageal Cancer
Interventions Celecoxib Cisplatin Esophagectomy Irinotecan Radiation Therapy
Updated 7 times since 2017 Last updated: Sep 18, 2017 Started: Jan 31, 2002 Primary completion: Aug 31, 2004 Completion: Sep 30, 2017

Listed as NCT00137852, this PHASE2 trial focuses on Esophageal Cancer and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Oct 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

  1. Feb 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Pharmacia
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States